<DOC>
	<DOCNO>NCT02828930</DOCNO>
	<brief_summary>The purpose single-center , open-label , non-randomized study assess excretion balance , pharmacokinetics , metabolism absolute oral bioavailability [ 14C ] -labeled idasanutlin administer orally [ 13C ] -labeled idasanutlin administer intravenously single cohort eligible participant . Participants screen participation study within 21 day receive first dose study drug Day 1 . Treatment period continue Day 28 participant enter 28 day follow-up optional treatment extension idasanutlin , depend safety parameter per opinion Investigator .</brief_summary>
	<brief_title>A Study Determine Excretion Balance , Pharmacokinetics , Metabolism Absolute Oral Bioavailability Single Oral Dose 14C-Labeled Idasanutlin Intravenous Tracer Dose 13C-Labeled Idasanutlin Single Cohort Participants With Solid Tumors ( Malignancies )</brief_title>
	<detailed_description />
	<criteria>Eastern Cooperative Oncology Group ( ECOG ) performance status 0 2 , discretion Investigator Histologically cytologically confirm advanced malignancy , except leukemia lymphoma Measureable evaluable disease Response evaluation criterion solid tumor ( RECIST ) version 1.1 , single active malignancy previous 3 5 year prior administration study drug Life expectancy least 12 week Participants take opioid analgesic pain stable pain palliative care bowel regimen one month prior first dose study medication Adequate bone marrow , hepatic , renal function Agreement remain abstinent use contraceptive method specify study History form leukemia , except Stage 0 1 chronic lymphocytic leukemia , require treatment addition underlie malignancy Have receive hormonal therapy within two week prior first dose study drug Have preexist gastrointestinal disorder may interfere proper absorption drug History seizure disorder unstable Central Nervous System metastases ( participant stable CNS metastasis allow ) Have severe and/or uncontrolled medical condition condition could affect participation study Receive certain per protocol prohibit medication study . These medication must discontinue 7 day prior start study drug Have bone marrow disorder , electrolyte imbalance , infrequent bowel movement ( less per 48 hour ) , coagulopathy , platelet disorder history nondrug induce thrombocytopenia Positive human immunodeficiency virus currently receive combination antiretroviral therapy Regular work ionize radiation radioactive material treat radiotherapy within 3 week prior first dose study drug Refuse potentially receive blood product and/or hypersensitivity blood product</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>